Error loading player: No playable sources found
42538
Workshop II: Analytical Evolution: Understanding Novel Modalities
Date
July 18, 2022
This product is not available for individual purchase, but it is available as part of the following products:
Safe, stable, and effective biopharmaceuticals require an in-depth understanding of biophysical, biochemical, and bio-functional attributes as well as the correlation between these properties. To advance products through phases of development, from candidate selection to commercial manufacturing, product characterization must evolve to inform refined process development that facilitates the manufacturing of products with sufficient control over safety, efficacy, purity, quality, and strength.
There is an ever-growing diversity of new modalities in biopharmaceuticals such as multi-specifics, ADCs, mRNA, and nanoparticle modalities. Along with this expansion of therapeutic modalities and novel mechanisms of action, the characterization of such products accordingly requires unique strategies – new techniques or new approaches using existing techniques. This session aims to discuss product understanding of novel modalities along with the challenges in establishing the appropriate and biologically-relevant critical quality attributes that is the foundation of the control strategy for these new products.
Session Speakers:
13:50 - 14:15
Characterization of Novel Biological Product Modalities: A Regulatory Perspective
Leslie Rivera Rosado, CDER, FDA
14:15 - 14:40
Characterization of mRNA Fragments to Evaluate Risk of Truncated or Off-Target Antigen Expression
Thomas Lerch, Pfizer, Inc.
14:40 - 15:05
Process Development Challenges for Bi-specific/Multi-specific Drug Development
Twinkle Christian, Amgen Inc.
There is an ever-growing diversity of new modalities in biopharmaceuticals such as multi-specifics, ADCs, mRNA, and nanoparticle modalities. Along with this expansion of therapeutic modalities and novel mechanisms of action, the characterization of such products accordingly requires unique strategies – new techniques or new approaches using existing techniques. This session aims to discuss product understanding of novel modalities along with the challenges in establishing the appropriate and biologically-relevant critical quality attributes that is the foundation of the control strategy for these new products.
Session Speakers:
13:50 - 14:15
Characterization of Novel Biological Product Modalities: A Regulatory Perspective
Leslie Rivera Rosado, CDER, FDA
14:15 - 14:40
Characterization of mRNA Fragments to Evaluate Risk of Truncated or Off-Target Antigen Expression
Thomas Lerch, Pfizer, Inc.
14:40 - 15:05
Process Development Challenges for Bi-specific/Multi-specific Drug Development
Twinkle Christian, Amgen Inc.
Related Products
Workshop III: Back to the Future: Leveraging Existing Playbooks to Create Robust Manufacturing Processes for Novel Modalities
In recent years there has been a significant effort to expand the types of modalities used to target various disease pathways or for use as a vaccine…
Workshop IV: Connecting the Dots: Turning the Mechanism of Action of Novel Modalities Into a Suitable Potency Assay
Potency assays are an integral part of the overall control strategy and should be designed for each product to measure its specific ability or capacity to effect a given result…
Workshop I: Innovation and Science: Therapies of the Future
Monoclonal antibody-like molecules, including bi- and tri-specifics, Fc-fusion proteins and antibody-drug conjugates, have become prominent as the next generation therapies in development…
